Feasibility of Multiple Burr Hole With Erythropoietin in Acute Moyamoya Patients
Background and Purpose—In patients with acute symptomatic moyamoya (<2 weeks), the feasibility of a combination therapy of multiple burr hole procedure under local anesthesia and intravenous erythropoietin pretreatment was assessed. We also identified the factors associated with transdural revascularization.
Methods—In this prospective single-arm study, perfusion-impaired patients presenting with transient ischemic attack or acute cerebral infarction were assessed. Combination therapy was performed to patients lacking transdural collaterals. Primary outcomes were evaluated clinically with modified Rankin Scale scores and radiologically with revascularization success (transhemispheric, trans-burr hole, and sufficient revascularizations [filling ≥33% of ipsilateral supratentorium]) at 6 months. Treatment-related adverse events were analyzed in 3 phases: pre burr hole, post burr hole, and after-discharge as secondary outcome. Factors associated with sufficient revascularization were investigated.
Results—Fifty hemispheres from 37 patients were included. Compared with discharge, modified Rankin scale score at 6 months significantly improved (2.0 [0.0–5.0] versus 1.0 [0.0–4.0]; P<0.001). Majority had successful revascularization: trans-burr hole arteriogenesis (89.5%), transhemispheric arteriogenesis (98.0%), and sufficient revascularization (52.0%). There was no significant pre burr hole or post burr hole complication. Two (5.4%) transient ischemic attack and 1 (2.7%) cerebral infarction occurred after discharge. Presentation with acute infarction (odds ratio, 4.8; 95% confidence interval, 1.1–21.4), ipsilateral basal moyamoya vessels (odds ratio, 13.9; 95% confidence interval, 1.3–144.2), and delayed mean transit time (odds ratio, 3.9; 95% confidence interval, 1.3–12.2) predicted sufficient revascularization.
Conclusions—Combination therapy allows safe and effective revascularization in moyamoya patients with acute ischemic presentation.
- Received September 25, 2017.
- Revision received February 14, 2018.
- Accepted March 12, 2018.
- © 2018 American Heart Association, Inc.